163 related articles for article (PubMed ID: 29301580)
1. Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers.
Costa MB; Picon PD; Sander GB; Cuni HN; Silva CV; Meireles RP; Góes ACMA; Batoreu NM; Maia MLS; Albuquerque EM; Matos DCS; Saura PL
BMC Pharmacol Toxicol; 2018 Jan; 19(1):1. PubMed ID: 29301580
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
Brennan BJ; Xu ZX; Grippo JF
Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
[TBL] [Abstract][Full Text] [Related]
4. A selective and sensitive UPLC-ESI-MS/MS method for quantification of Pegylated Interferon Alfa-2b in human serum using signature peptide-based quantitation.
Bob Kusuma M; Kashibhatta R; Jagtap SS; Nadawade V; Adsul S; Moorkoth S; Bhat K; Mody R; Vithala P
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1180():122883. PubMed ID: 34438247
[TBL] [Abstract][Full Text] [Related]
5. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
Reddy KR
Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
[TBL] [Abstract][Full Text] [Related]
6. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
7. Population PK-PD Model of Pegylated Interferon Alfa-2a in Healthy Korean Men.
Jung YS; Chae D; Park K
J Pharm Sci; 2018 Dec; 107(12):3171-3178. PubMed ID: 30179597
[TBL] [Abstract][Full Text] [Related]
8. Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice.
Elsadek NE; Hondo E; Shimizu T; Takata H; Abu Lila AS; Emam SE; Ando H; Ishima Y; Ishida T
Mol Pharm; 2020 Aug; 17(8):2964-2970. PubMed ID: 32519877
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C.
Jen JF; Glue P; Ezzet F; Chung C; Gupta SK; Jacobs S; Hajian G
Clin Pharmacol Ther; 2001 Jun; 69(6):407-21. PubMed ID: 11406738
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
11. Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.
Huang YW; Qin A; Fang J; Wang TF; Tsai CW; Lin KC; Teng CL; Larouche R
Br J Clin Pharmacol; 2022 May; 88(5):2396-2407. PubMed ID: 34907578
[TBL] [Abstract][Full Text] [Related]
12. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.
Bruno R; Sacchi P; Cima S; Maiocchi L; Novati S; Filice G; Fagiuoli S
J Viral Hepat; 2012 Jan; 19 Suppl 1():33-6. PubMed ID: 22233411
[TBL] [Abstract][Full Text] [Related]
13. Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders.
Fülöp B; Biermer M; Cornberg M; Wedemeyer H; Port K; Heyne R; Zeuzem S; Peiffer KH; Welzel T; Herber A; Buggisch P; Moser C; Stoll S; Alshuth U; Berg T
Liver Int; 2015 Oct; 35(10):2275-84. PubMed ID: 25801095
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of peginterferons.
Zeuzem S; Welsch C; Herrmann E
Semin Liver Dis; 2003; 23 Suppl 1():23-8. PubMed ID: 12934165
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.
Zheng L; Li MP; Gou ZP; Wang Y; Xu N; Cai YM; Luo H
Br J Clin Pharmacol; 2015 Apr; 79(4):650-9. PubMed ID: 25297637
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers.
Garcia-Garcia I; Gonzalez-Delgado CA; Valenzuela-Silva C; Hernandez-Bernal F; Ferrero-Bibilonia J; Soto-Hernandez R; Cervantes-Llano M; Ducongé J; Correa-Fernandez A; Olivera-Ruano L; Lopez-Saura P
Drugs R D; 2004; 5(5):271-80. PubMed ID: 15357626
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
García-Vega Y; García-García I; Collazo-Caballero SE; Santely-Pravia EE; Cruz-Ramírez A; Tuero-Iglesias AD; Alfonso-Alvarado C; Cabrera-Placeres M; Castro-Basart N; Duncan-Roberts Y; Carballo-Treto TI; Soto-Matos J; Izquierdo-Toledo Y; Vázquez-Blomquist D; García-Iglesias E; Bello-Rivero I
BMC Pharmacol Toxicol; 2012 Dec; 13():20. PubMed ID: 23272809
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
Baker DE
Rev Gastroenterol Disord; 2003; 3(2):93-109. PubMed ID: 12776006
[TBL] [Abstract][Full Text] [Related]
20. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
